Print Page     Close Window     

Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
04/12/17Cipher Pharmaceuticals Proposes Adding Robert Tessarolo and Arthur Deboeck to Board of Directors
Mark Beaudet expected to be appointed new independent Chair of BoardMISSISSAUGA, ONTARIO, April 12, 2017 – Cipher Pharmaceuticals Inc. (TSX:CPH) (“Cipher” or “the Company”) today announced several proposed changes to its Board of Directors, to be voted upon at the Company’s Annual Meeting on May 11, 2017. The items of business to be considered at the meeting are described in the Notice of Annual Meeting of Shareholders and accompanying Management Information Circular available at www.sedar... 
Printer Friendly Version
04/03/17Cipher Pharmaceuticals Announces Amendment to Debt Agreement and Partial Prepayment
MISSISSAUGA, ONTARIO, April 3, 2017 – Cipher Pharmaceuticals Inc. (TSX:CPH) (“Cipher” or “the Company”) announced today that it has completed an amendment to the securities purchase agreement (the “Amendment”) with investment funds managed by Athyrium Capital Management (“Athyrium”). Unless otherwise noted, all figures are in U.S. currency.Among the key changes, the Amendment allows Cipher to prepay $20.0 million of the $40.0 million Senior Secured Notes that are currently outstanding wit... 
Printer Friendly Version
03/20/17Cipher Pharmaceuticals Appoints Robert D. Tessarolo as CEO
MISSISSAUGA, ONTARIO, March 20, 2017 – Cipher Pharmaceuticals Inc. (TSX:CPH) (“Cipher” or “the Company”) announced today that veteran pharmaceutical industry executive Robert D. Tessarolo has been appointed President and Chief Executive Officer of Cipher, effective April 17, 2017.  Mr. Tessarolo will also be nominated for election as a director at the Company’s next annual general meeting in May 2017. Mr. Tessarolo has 22 years of experience in the pharmaceutical industry spanning busi... 
Printer Friendly Version
03/02/17Cipher Pharmaceuticals Reports 2016 Q4 & Year-End Financial Results
MISSISSAUGA, ON, March 2, 2017 - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and 12 months ended December 31, 2016. Unless otherwise noted, all figures are in U.S. currency. Financial Highlights for Q4 2016 (all figures compared to Q4 2015, unless otherwise noted) Total revenue of $10.7 million, an increase of 10% from $9.7 million in Q4 2015. Licensing revenue of $5.4 million, compared with $6.6 millio... 
Printer Friendly Version
02/16/17Notice of Cipher Pharmaceuticals Inc. Q4 and Year-End 2016 Conference Call
MISSISSAUGA, ON, Feb. 16, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it will host a conference call its Q4 and full-year 2016 financial results on Thursday, March 2, 2017. Q4 AND YEAR-END 2016 CONFERENCE CALL WHEN: Thursday, March 2, 2017 at 8:30AM ET CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through or An archived replay of the webcast wi... 
Printer Friendly Version
<< First | Previous | Next | Last >>